11315 studies found for:    NCI
Show Display Options
Rank Status Study
1 Not yet recruiting Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Conditions: Grade 1 Endometrial Endometrioid Adenocarcinoma;   Grade 2 Endometrial Endometrioid Adenocarcinoma;   Grade 3 Endometrial Endometrioid Adenocarcinoma;   Uterine Corpus Adenosarcoma
Interventions: Drug: Entinostat;   Procedure: Hysterectomy;   Other: Laboratory Biomarker Analysis;   Drug: Medroxyprogesterone Acetate
2 Not yet recruiting Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Metastatic Malignant Neoplasm in the Lymph Nodes;   Recurrent Gastric Carcinoma;   Stage IV Gastric Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Biological: Ramucirumab
3 Not yet recruiting Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer
Conditions: Colorectal Adenocarcinoma;   High-Frequency Microsatellite Instability;   Stage IV Colorectal Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
4 Not yet recruiting Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive
Interventions: Drug: Afimoxifene;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Tamoxifen Citrate
5 Recruiting Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Conditions: Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Ropidoxuridine;   Radiation: Whole-Brain Radiotherapy
6 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
7 Not yet recruiting Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Condition: Recurrent Glioblastoma
Interventions: Biological: Bevacizumab;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
8 Not yet recruiting Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Conditions: EGFR Activating Mutation;   EGFR NP_005219.2:p.T790M;   Metastatic Malignant Neoplasm in the Brain;   Non-Small Cell Lung Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
9 Not yet recruiting Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
Condition: Cirrhosis
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Simvastatin
10 Not yet recruiting Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Talimogene Laherparepvec
11 Not yet recruiting Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
Condition: Colorectal Adenoma
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration
12 Not yet recruiting Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Conditions: Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
13 Recruiting Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer;   Stage I Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
14 Not yet recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
15 Not yet recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Conditions: Leiomyosarcoma;   Liposarcoma;   Sarcoma Differentiation Score 2;   Sarcoma Differentiation Score 3;   Stage IA Soft Tissue Sarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIA Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Biological: Talimogene Laherparepvec
16 Not yet recruiting Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Recurrent Cervical Carcinoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis
17 Recruiting Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Conditions: Rectal Adenocarcinoma;   Stage II Rectal Cancer;   Stage III Rectal Cancer
Interventions: Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Veliparib
18 Not yet recruiting ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
Conditions: Oral Cavity Neoplasm;   Oropharyngeal Neoplasm;   Stage I Oral Cavity Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oral Cavity Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet;   Other: Pharmacological Study;   Other: Placebo
19 Not yet recruiting Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability
Conditions: Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Microsatellite Instability;   Stage IIIA Colon Cancer;   Stage IIIB Colon Cancer;   Stage IIIC Colon Cancer
Interventions: Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
20 Not yet recruiting Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.